Loading stock data…
Stoke Therapeutics (STOK)
$29.30-0.35 (-1.18%)
Market ClosedLast close Jul 24
Stoke Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stoke Therapeutics, Inc. in the Healthcare sector is trading at $29.30 with a market capitalization of $1.8B. Wall Street consensus targets $45.82 (11 analysts), implying a +56.4% move over the next 12 months. The stock is currently 27% below its 52-week high of $40.22, remaining 7.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +56.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.23M↑ | $1.40M↓ | $10.63M↓ | $13.82M↓ | $158.57M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$53.42M↑ | -$61.44M↓ | -$43.09M↓ | -$27.30M↓ | $111.24M |
| Net Income | -$50.00M↑ | -$57.93M↓ | -$38.35M↓ | -$23.48M↓ | $112.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisen...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.81B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.99%
Volume
Today's trading volume
412,210
Recent News
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates
Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 7, Stoke Therapeutics, Inc. (NASDAQ:STOK) reported Q1 results and business updates. The company stated that four years of data from “Phase 1/2a open-label extension” studies revealed statistically meaningful gains in cognition and behavior, […]
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its latest quarterly results and things are looking bullish...